Professor D L Scott, King's College Hospital, East Dulwich Grove, Dulwich, London SE22 8PT, UKleigh.joyce{at}kcl.ac.uk OBJECTIVE Recent studies have demonstrated the short term efficacy of leflunomide ...

Correspondence to Dr Sylvain Mathieu, Rheumatology Department, Gabriel Montpied Teaching Hospital, 63003 Clermont-Ferrand, France; smathieu{at}chu-clermontferrand.fr We searched PubMed to find reports ...

1 Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria 2 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria 3 Department of Internal ...

When a year closes and gives way to its successor, it is good to pause for breath to reflect on the achievements of the past and contemplate the prospects for the incoming year. So when looking back ...

Objective: To create minimal disease activity (MDA) criteria for psoriatic arthritis (PsA). With recent therapeutic advances, this is now a goal for treatment and may represent a measure to compare ...

Background: Chronic low back pain (LBP), the leading symptom of ankylosing spondylitis (AS) and undifferentiated axial spondyloarthritis (SpA), precedes the development of radiographic sacroiliitis, ...

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid ...

1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...

Correspondence to Dr David T Ewart, Division of Rheumatic and Autoimmune Diseases, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA; ewar0001{at}umn.edu and ...

Over the past decades, the concept of ‘remission’ has emerged as a moniker for the disease state one would ideally like to achieve when a ‘cure’—the ultimate goal of medical intervention—cannot ...

Background NeceSSity stands for “New Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients”. International consortium involving 25 partners (20 ...

Objective To assess the efficacy and safety of the type I interferon receptor antibody, anifrolumab, in patients with active, biopsy-proven, Class III/IV lupus nephritis. Methods This phase II ...